Background: Despite the wide array of treatments available for rheumatoid arthritis (RA), some patients continue to report unmet clinical needs. We investigated the extent of inadequate disease control in patients with RA. Methods: Data were drawn from the Adelphi 2014 RA Disease Specific Program in France, Germany, Italy, Spain and the UK. Rheumatologists provided patient demographics, comorbidities, satisfaction with RA control and other clinical details. Patients reported their level of satisfaction and completed the EuroQoL 5-Dimensions health questionnaire and Work Productivity and Activity Impairment questionnaire. Patients had been on their current therapy ≥3 months and had 28-joint disease activity scores (DAS28) reported. Adequatel...
Background: Data regarding the real-life predictors of low disease activity (LDA) in rheumatoid arth...
Background: It has been shown previously that patients with rheumatoid arthritis (RA) can generate a...
Objectives The emergence of targeted therapy is changing rheumatoid arthritis (RA) management, but r...
Background Despite the wide array of treatments available for rheumatoid arthritis (RA), some patien...
Background: Patients’ needs and perspectives are important determinants of treatment success in rheu...
Background: Patients' needs and perspectives are important determinants of treatment success in rheu...
Objectives: To evaluate the disease activity and current pharmacological interventions used to achie...
Objectives: Patients with difficult-to-treat rheumatoid arthritis (RA) remain symptomatic despite tr...
Objective: To evaluate the nature and burden of residual disease in rheumatoid arthritis (RA) in pat...
OBJECTIVE: The observational RAPSODIA (RA, PsA and spondylitis including AS) study was planned to as...
Introduction: Rheumatoid arthritis (RA) is a chronic progressive autoimmune rheumatic disease that p...
Introduction: Difficult-to-treat rheumatoid arthritis (RA) is a significant clinical problem despit...
Objective To evaluate the nature and burden of residual disease in rheumatoid arthritis (RA) in pati...
Objective To evaluate treatment satisfaction, disease outcomes, and perspectives of patients with po...
Objective The aim was to reveal the everyday impact of living with RA in people not treated with ad...
Background: Data regarding the real-life predictors of low disease activity (LDA) in rheumatoid arth...
Background: It has been shown previously that patients with rheumatoid arthritis (RA) can generate a...
Objectives The emergence of targeted therapy is changing rheumatoid arthritis (RA) management, but r...
Background Despite the wide array of treatments available for rheumatoid arthritis (RA), some patien...
Background: Patients’ needs and perspectives are important determinants of treatment success in rheu...
Background: Patients' needs and perspectives are important determinants of treatment success in rheu...
Objectives: To evaluate the disease activity and current pharmacological interventions used to achie...
Objectives: Patients with difficult-to-treat rheumatoid arthritis (RA) remain symptomatic despite tr...
Objective: To evaluate the nature and burden of residual disease in rheumatoid arthritis (RA) in pat...
OBJECTIVE: The observational RAPSODIA (RA, PsA and spondylitis including AS) study was planned to as...
Introduction: Rheumatoid arthritis (RA) is a chronic progressive autoimmune rheumatic disease that p...
Introduction: Difficult-to-treat rheumatoid arthritis (RA) is a significant clinical problem despit...
Objective To evaluate the nature and burden of residual disease in rheumatoid arthritis (RA) in pati...
Objective To evaluate treatment satisfaction, disease outcomes, and perspectives of patients with po...
Objective The aim was to reveal the everyday impact of living with RA in people not treated with ad...
Background: Data regarding the real-life predictors of low disease activity (LDA) in rheumatoid arth...
Background: It has been shown previously that patients with rheumatoid arthritis (RA) can generate a...
Objectives The emergence of targeted therapy is changing rheumatoid arthritis (RA) management, but r...